Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Digital Biomarkers|February 26, 2020
Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson DiseaseBenjamin D Wissel, Georgia Mitsi, Alok K Dwivedi, et al.
Annals of Neurology|September 12, 2017
Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegenerationAlberto J Espay, Gustavo A Da Prat, Alok K Dwivedi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observationsAlberto J Espay, Andrew P Duker, Robert Chen, et al.
Biomedicines|January 8, 2025
Studying Rare Movement Disorders: From Whole-Exome Sequencing to New Diagnostic and Therapeutic Approaches in a Modern Genetic ClinicLuca Marsili, Kevin R Duque, Jesus Abanto, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 18, 2018
Functional neurological disorders in Parkinson diseaseBenjamin D Wissel, Alok K Dwivedi, Aristide Merola, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 21, 2017
Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registryAristide Merola, Alfonso Fasano, Anhar Hassan, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
JAMA Neurology|September 15, 2025
Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson DiseasePhilip A Starr, Rajat S Shivacharan, Edward Goldberg, et al.
The Lancet. Neurology|May 30, 2020
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled studyJerrold L Vitek, Roshini Jain, Lilly Chen, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 4